The Benefits Of Cryoablation In Patients Undergoing Total Knee Arthroplasty
Launched by NYU LANGONE HEALTH · May 19, 2025
Trial Information
Current as of June 26, 2025
Not yet recruiting
Keywords
ClinConnect Summary
This clinical trial is looking at a treatment called cryoablation to see if it can help reduce pain and the need for pain medications after patients have total knee replacement surgery. The study will compare two groups: one group will receive the usual knee surgery, while the other group will receive the surgery along with cryoablation, which uses cold temperatures to numb the area and potentially lessen pain.
To participate in this study, patients need to be scheduled for a total knee replacement due to conditions like osteoarthritis or inflammatory arthritis. However, those with certain cold-related health issues or those needing surgery for fractures or infections will not be eligible. The trial is currently not recruiting participants yet, so it’s a great opportunity to learn more about the potential benefits of cryoablation in managing pain after knee surgery. Participants will help researchers understand how effective this treatment can be in improving recovery outcomes.
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • Patients are candidates for elective primary total knee arthroplasty for a diagnosis of osteoarthritis or inflammatory arthritis.
- • Patients have been medically cleared and scheduled for surgery
- Exclusion Criteria:
- • Patients with cold-related conditions (cryoglobulinemia, paroxysmal cold hemoglobinuria, cold urticaria, and Raynaud's disease)
- • Surgery for fracture, infection, or malignancy
About Nyu Langone Health
NYU Langone Health is a premier academic medical center located in New York City, renowned for its commitment to advancing healthcare through innovative research and clinical excellence. As a leading sponsor of clinical trials, NYU Langone Health integrates cutting-edge scientific inquiry with patient-centered care, striving to develop new therapies and improve health outcomes across a wide range of medical conditions. The institution is dedicated to fostering collaboration among researchers, clinicians, and patients, ensuring rigorous adherence to ethical standards and regulatory guidelines in all clinical research initiatives. By leveraging its extensive resources and expertise, NYU Langone Health aims to contribute significantly to the advancement of medical knowledge and the enhancement of patient care.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
New York, New York, United States
Patients applied
Trial Officials
Joshua Rozell, MD
Principal Investigator
NYU Langone Health
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported